AMBER REED: Open Payments
NPI 1093300436 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,098 in 44 payments from 13 companies in 2025. Trend: 2023 $126 · 2024 $1,117 · 2025 $1,098
Food & beverage: $1,050Consulting: $48
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $316 |
| GENZYME CORPORATION | 8 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $139 |
| Pharming Healthcare, Inc. | 2 | $124 |
| Novartis Pharmaceuticals Corporation | 4 | $95 |
| Blueprint Medicines Corporation | 2 | $49 |
| ADMA BioManufacturing LLC | 3 | $48 |
| BioCryst US Sales Co., LLC | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $32 |
Products named: DUPIXENT, AIRSUPRA, TEZSPIRE, RUCONEST, CUVITRU, Rhapsido, TAKHZYRO, AYVAKIT.
Industry payments across AZ — which companies pay providers there.
